Pancreatic Cancer Research

ResearcherUniversity of PaduaActive in the last 2 years

Aya Maekawa

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3127-9978; OpenAlex author ID A5017346046, A5114156707. Sources: OpenAlex.

Their work

Papers
18 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
91
Papers, trials and grants by year

2020: 1 paper · 2021: 1 paper · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 6 papers · 2026: 7 papers

Papers 18

  1. Conversion surgery for unresectable pancreatic ductal adenocarcinoma with liver metastasis at initial diagnosis: a nationwide multicenter study. Co-author DOI 10.1007/s00535-026-02432-2↗
  2. The future of integrated treatment for PDAC: Learning from the past, advancing for the better. Co-author DOI 10.1016/j.dld.2026.09.002↗
  3. Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-18806-4↗
  4. ASO Visual Abstract: Surgical Challenges Associated with Collateral Veins Formation in Pancreatic Cancer with Vein Resection. Co-author DOI 10.1245/s10434-025-19046-2↗
  5. Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapies are Associated with… Co-author DOI 10.1245/s10434-026-19939-w↗
  6. ASO Visual Abstract: Treatment Strategies and Outcomes for Single-Site Recurrent Pancreatic Ductal Adenocarcinoma After Curative-Intent Surgery: Local Therapie… Co-author DOI 10.1245/s10434-026-19987-2↗
  7. ASO Author Reflections: Local Therapy for Single-Site Recurrent Pancreatic Cancer: Anatomy, Biology, and Selection. Co-author DOI 10.1245/s10434-026-20012-9↗
  8. Clinical implications of disappearing pancreatic cancer liver metastases: Lessons from colorectal liver metastases. Co-author DOI 10.1016/j.ejso.2025.109635↗
  9. Exploring the role of CA 19-9 dynamics in pancreatic cancer multidisciplinary treatment: Proposal of the PANC classification. Co-author DOI 10.1016/j.surg.2025.109783↗
  10. Arterial resection and divestment in pancreatic cancer surgery in the era of multidisciplinary treatment: decadal comparative study. Co-author DOI 10.1093/bjsopen/zraf026↗
  11. Blood Group Antigen Expression in Blood and Tumor in Relation to Survival Outcomes in Resected Pancreatic Cancer, Overall and by Adjuvant Chemotherapy Regimens. Co-author DOI 10.1245/s10434-025-17289-7↗
  12. Resectable Pancreatic Cancer with CA19-9 > 500 U/mL: A Biological Indicator for Survival Benefit with Intensive Neoadjuvant Chemotherapy. Co-author DOI 10.1245/s10434-025-17407-5↗
  13. ASO Author Reflections: Optimizing Treatment for Resectable Pancreatic Cancer: CA19-9 > 500 U/mL as a Biologic Indicator for Neoadjuvant Therapy. Co-author DOI 10.1245/s10434-025-17458-8↗
  14. Caveolin-1 expression is a predictor of survival and recurrence patterns in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2024.10.001↗
  15. A proposal of ABCD metastasectomy criteria for synchronous/metachronous metastatic pancreatic cancer in the era of multidisciplinary treatment. First author DOI 10.1093/bjs/znad417↗
  16. "Conversion surgery" for locally advanced pancreatic cancer: A position paper by the study group at the joint meeting of the International Association of Pancr… Co-author DOI 10.1016/j.pan.2023.06.005↗
  17. Prediction of early recurrence of pancreatic ductal adenocarcinoma after resection. Co-author DOI 10.1371/journal.pone.0249885↗
  18. Successful conversion surgery of distal pancreatectomy with celiac axis resection (DP-CAR) with double arterial reconstruction using saphenous vein grafting fo… Co-author DOI 10.1186/s40792-020-01082-7↗

Closest collaborators

The 25 strongest of 91 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Atsushi Oba · 10 shared papers, 2023–2026 · strength 2.02
  2. Naoki Sasahira · 10 shared papers, 2023–2026 · strength 1.95
  3. Hiromichi Ito · 8 shared papers, 2024–2026 · strength 1.65
  4. Masato Ozaka · 8 shared papers, 2024–2026 · strength 1.65
  5. Yosuke Inoue · 8 shared papers, 2023–2026 · strength 1.61
  6. Giovanni Marchegiani · 4 shared papers, 2026 · strength 1.53
  7. Yu Takahashi · 7 shared papers, 2023–2026 · strength 1.28
  8. Yoshihiro Ono · 6 shared papers, 2024–2026 · strength 1.22
  9. Kojiro Omiya · 6 shared papers, 2024–2025 · strength 1.21
  10. Takashi Sasaki · 6 shared papers, 2023–2026 · strength 1.14
  11. Giampaolo Perri · 3 shared papers, 2026 · strength 1.03
  12. Takafumi Mie · 4 shared papers, 2025 · strength 0.88
  13. Yosuke Inoue · 4 shared papers, 2024–2026 · strength 0.77
  14. Manabu Takamatsu · 4 shared papers, 2024–2025 · strength 0.74
  15. Yuki Hirose · 4 shared papers, 2024–2025 · strength 0.74
  16. Yu Takahashi · 3 shared papers, 2025–2026 · strength 0.71
  17. Yoshihiro Ono · 3 shared papers, 2025 · strength 0.68
  18. Umberto Cillo · 2 shared papers, 2026 · strength 0.60
  19. Agata Grochowska · 2 shared papers, 2026 · strength 0.60
  20. Tatsunori Suzuki · 3 shared papers, 2024–2026 · strength 0.52
  21. Gabriele Capurso · 1 shared paper, 2026 · strength 0.50
  22. Tatsunori Miyata · 2 shared papers, 2026 · strength 0.48
  23. Tomotaka Kato · 2 shared papers, 2026 · strength 0.48
  24. Masaaki Iwatsuki · 2 shared papers, 2026 · strength 0.48
  25. Daisuke Ban · 3 shared papers, 2020–2025 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.